Lirum Therapeutics (Lirum Therapeutics) Days Payable : 0.00 (As of Dec. 2023)

View and export this data going back to 2024. Start your Free Trial

What is Lirum Therapeutics Days Payable?

Lirum Therapeutics's average Accounts Payable for the three months ended in Dec. 2023 was $0.75 Mil. Lirum Therapeutics's Cost of Goods Sold for the three months ended in Dec. 2023 was $0.00 Mil.

The historical rank and industry rank for Lirum Therapeutics's Days Payable or its related term are showing as below:

LRTX's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 148.01
* Ranked among companies with meaningful Days Payable only.

Lirum Therapeutics's Days Payable stayed the same from Dec. 2021 (0.00) to Dec. 2023 (0.00). stayed the same

Lirum Therapeutics Days Payable Historical Data

The historical data trend for Lirum Therapeutics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lirum Therapeutics Days Payable Chart

Lirum Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Days Payable

Lirum Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Sep23	Dec23
Days Payable	-	-	-	-	-

Competitive Comparison of Lirum Therapeutics's Days Payable

For the Biotechnology subindustry, Lirum Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lirum Therapeutics's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lirum Therapeutics's Days Payable distribution charts can be found below:

* The bar in red indicates where Lirum Therapeutics's Days Payable falls into.

Lirum Therapeutics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Lirum Therapeutics's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (0.235	+	0.798)	/	2 )	/	0	*	365
=	0.5165					/	0	*	365
=	N/A

Lirum Therapeutics's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

	Days Payable (Q: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2023 )	+	Accounts Payable (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (0.706	+	0.798)	/	2 )	/	0	*	365 / 4
=	0.752					/	0	*	365 / 4
=	N/A

Lirum Therapeutics Days Payable Related Terms

Thank you for viewing the detailed overview of Lirum Therapeutics's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Lirum Therapeutics (Lirum Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lirum Therapeutics Inc (NAS:LRTX) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

590 Madison Avenue, 21st Floor, New York, NY, USA, 10022

Website

https://www.lirumtx.com

Lirum Therapeutics Inc is clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases through the acquisition, development, and commercialization of novel drug candidates with compelling mechanisms of action, regulatory pathways, and commercial opportunities. Its product candidate, LX-101, formerly 765IGF-MTX, is a novel, clinical-stage, "next generation," precision-engineered targeted therapy directed to the IGF-1R.

Lirum Therapeutics (Lirum Therapeutics) Headlines

No Headlines